 NEW YORK, March 30, 2021 GLOBE NEWSWIRE -- Mesoblast Limited Nasdaq:MESO; ASX:MSB, global leader in allogeneic cellular medicines for inflammatory diseases, today provided an overview of the Companys recent operational highlights, as well as upcoming milestones. 